Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339291 | 0.80 | NOTUM (0.48) | LMNAMAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL18228687 | 0.78 | ATM (0.43) | LMNAMAPTALDH1A1 | |
| SCHEMBL7397076 | 0.77 | MAPK14 (0.41) | — | |
| SCHEMBL4600920 | 0.77 | GCGR (0.42) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL27783565 | 0.75 | GAA (0.39) | — | |
| SCHEMBL27958531 | 0.73 | NPC1 (0.39) | MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14840350 | 0.73 | — | — | |
| SCHEMBL27473801 | 0.73 | NPC1 (0.39) | LMNAALDH1A1CYP2D6MAPK1SMN1; SMN2 | |
| SCHEMBL4461211 | 0.73 | — | — | |
| SCHEMBL29045051 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759524-B2 | Production process of optically active 3-quinuclidinol derivative | NIPPON SODA CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20130225824-A1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2186812-B1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | NIPPON SODA CO (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8436181-B2 | Production process of optically active 3-quinuclidinol derivative | NIPPON SODA CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20100174081-A1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-07-08 | — | — | US | disclosed |
| EP-2186812-A1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | National University Corporation Hokkaido University (JP) | 2010-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225824-A1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | GRK7, NR2E3, GRK1 | LMNA 3080/4885MAPT 4844/4885MEN1 4122/4885 |
| US-20100174081-A1 | PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE | GRK7, NR2E3, GRK1 | LMNA 3080/4885MAPT 4844/4885MEN1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.